KR20230156107A - 전립선암의 치료 방법 - Google Patents

전립선암의 치료 방법 Download PDF

Info

Publication number
KR20230156107A
KR20230156107A KR1020237034510A KR20237034510A KR20230156107A KR 20230156107 A KR20230156107 A KR 20230156107A KR 1020237034510 A KR1020237034510 A KR 1020237034510A KR 20237034510 A KR20237034510 A KR 20237034510A KR 20230156107 A KR20230156107 A KR 20230156107A
Authority
KR
South Korea
Prior art keywords
prostate cancer
compound
cells
approximately
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237034510A
Other languages
English (en)
Korean (ko)
Inventor
마르티나 말라테스타
엘렌 호프 필바로프
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브리스톨-마이어스 스큅 컴퍼니 filed Critical 브리스톨-마이어스 스큅 컴퍼니
Publication of KR20230156107A publication Critical patent/KR20230156107A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020237034510A 2021-03-12 2022-03-10 전립선암의 치료 방법 Pending KR20230156107A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163160319P 2021-03-12 2021-03-12
US63/160,319 2021-03-12
PCT/US2022/019662 WO2022192481A1 (en) 2021-03-12 2022-03-10 Methods of treating prostate cancer

Publications (1)

Publication Number Publication Date
KR20230156107A true KR20230156107A (ko) 2023-11-13

Family

ID=80952117

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237034510A Pending KR20230156107A (ko) 2021-03-12 2022-03-10 전립선암의 치료 방법

Country Status (6)

Country Link
US (1) US12016847B2 (https=)
EP (1) EP4304589A1 (https=)
JP (1) JP2024510975A (https=)
KR (1) KR20230156107A (https=)
CN (1) CN117241797A (https=)
WO (1) WO2022192481A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20220630A (es) 2020-05-09 2023-01-23 Arvinas Operations Inc Métodos para fabricar un compuesto bifuncional, formas ultrapuras del compuesto bifuncional y formas de dosificación que comprenden el mismo
TW202535392A (zh) 2023-12-08 2025-09-16 美商亞文納營運公司 使用雄性素受體降解劑治療脊髓延髓性肌肉萎縮

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI477503B (zh) 2008-10-31 2015-03-21 Medivation Technologies Inc 含有剛性部分之吡啶并〔４，３－ｂ〕吲哚
CN102257076B (zh) 2008-12-18 2014-07-30 纳幕尔杜邦公司 具有新颜料的粉末涂料组合物
US8580399B2 (en) 2011-04-08 2013-11-12 Universal Display Corporation Substituted oligoazacarbazoles for light emitting diodes
WO2013046635A1 (ja) 2011-09-28 2013-04-04 出光興産株式会社 有機エレクトロルミネッセンス素子用材料及びそれを用いた有機エレクトロルミネッセンス素子
UA115576C2 (uk) 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
EP2961747B1 (en) 2013-02-27 2017-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
US9492460B2 (en) 2013-02-27 2016-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
EP2970312B1 (en) 2013-03-11 2017-11-15 The Regents of The University of Michigan Bet bromodomain inhibitors and therapeutic methods using the same
KR102457145B1 (ko) * 2013-12-24 2022-10-19 브리스톨-마이어스 스큅 컴퍼니 항암제로서의 트리시클릭 화합물
US9458156B2 (en) * 2014-12-23 2016-10-04 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
WO2015131005A1 (en) * 2014-02-28 2015-09-03 The Regents Of The University Of Michigan 9h-pyrimido[4,5-b]indoles and related analogs as bet bromodomain inhibitors
AU2015358334A1 (en) * 2014-12-05 2017-06-08 Dana-Farber Cancer Institute, Inc. Bromodomain inhibitor as adjuvant in cancer immunotherapy
WO2017216772A2 (en) * 2016-06-16 2017-12-21 The University Of Chicago Methods and compositions for treating breast and prostate cancer
WO2019080941A1 (en) 2017-10-27 2019-05-02 Jacobio-Beta Pharmaceuticals Co., Ltd. NEW TRICYCLIC COMPOUNDS
WO2021175432A1 (en) 2020-03-04 2021-09-10 Boehringer Ingelheim International Gmbh Method for administration of an anti cancer agent

Also Published As

Publication number Publication date
US12016847B2 (en) 2024-06-25
JP2024510975A (ja) 2024-03-12
EP4304589A1 (en) 2024-01-17
US20220296574A1 (en) 2022-09-22
WO2022192481A1 (en) 2022-09-15
CN117241797A (zh) 2023-12-15

Similar Documents

Publication Publication Date Title
KR20230147165A (ko) 전립선암을 치료하는 데 사용하기 위한 브로모도메인 (bet) 억제제
US8110550B2 (en) HDAC inhibitors and hormone targeted drugs for the treatment of cancer
EP1604665B1 (en) C-kit kinase inhibitor
JP5993074B2 (ja) 放射線直腸ｓ状結腸炎を処置するための組成物および方法
TWI873485B (zh) 用於治療癌症之方法及包含cdk2抑制劑及cdk4抑制劑之給藥方案
KR20230156107A (ko) 전립선암의 치료 방법
US8785423B2 (en) Compositions and methods of inducing endoplasmic reticulum stress response for the treatment of cell proliferative diseases
JP2018500299A (ja) 神経線維腫症２型に関連する腫瘍の治療のためのユビキチン−プロテアソーム系阻害剤の使用
KR20220025849A (ko) 미토콘드리아의 표적화 및 암 줄기 세포의 근절을 위한 카르보시아닌 화합물
US20130131156A1 (en) Cancer Treatment with Wortmannin Analogs
CA2362426A1 (en) Anticancer drug enhancer
CN107569485A (zh) 一种治疗braf抑制剂耐药型黑色素瘤的复方制剂
JPWO2006118212A1 (ja) 膵炎の予防および治療剤
HK40099691A (zh) 用於治疗前列腺癌的溴结构域(bet)抑制剂
WO2023133414A2 (en) Selective elimination of senescent cells by ferroptosis induction
US20100204286A1 (en) Method for reducing gastrointestinal adverse effects of cytotoxic agents
CN114177178A (zh) 一种石蒜碱的新应用：增强索拉菲尼治疗肝癌的敏感性
KR20230031443A (ko) 벤즈이미다졸 유도체를 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물
CN108434137B (zh) 一种治疗前列腺癌的组合物
CN115364083B (zh) 一种利多卡因衍生物在制备防治肠道屏障损伤产品中的应用
Xu et al. Ang II enhances atrial fibroblast autophagy and promotes atrial remodeling through the AT1-ERK-mTOR signaling pathway
JP2019505536A (ja) 肥満の処置のための方法及び医薬組成物
JP5976813B2 (ja) 癌を治療するための、特に、癌転移を予防および／または治療するための、３−（ｒ）−［３−（２−メトキシフェニルチオ）−２−（ｓ）−メチル−プロピル］アミノ−３，４−ジヒドロ−２ｈ−１，５−ベンゾオキサチエピンの使用
CN121895326A (zh) 一种泛kras突变抑制剂及其应用
US20050143450A1 (en) Alkyl PCDF as a treatment for prostate cancer

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20231010

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250310

Comment text: Request for Examination of Application